Rainbow Children's Medicare capacity ramp-up supports earnings growth despite near-term margin pressure

Investment View and Valuation

In its August 03, 2026 Q1FY27 result update, PL Research maintained its BUY rating on Rainbow Children's Medicare and raised its target price to Rs 1,900 from Rs 1,700. The target is based on 28 times pre-IndAS FY28E EV/EBITDA.

PL Research views Rainbow as a differentiated integrated multi-specialty paediatric hospital chain, supported by its asset-light hub-and-spoke model, full-time doctor engagement model, higher margins, strong free cash flow generation, net cash balance sheet and healthy return ratios. The broker expects profitability to improve as recently added capacity ramps up, following a 40 per cent increase in bed capacity over the past two years.

Q1FY27 Financial Performance

Rainbow Children's Medicare reported strong year-on-year growth in Q1FY27, with revenue exceeding PL Research's estimate and EBITDA broadly in line with expectations.

EBITDA margin declined by around 80 basis points year on year to 28.6 per cent. This reflected the operationalisation of 48 beds at HRBR, Bengaluru, during Q1 and continuing losses at the 90-bed Electronic City unit, which opened in Q4FY26. Pre-IndAS EBITDA was Rs 1,100 million, up 33 per cent year on year, with a 23 per cent operating margin.

Operating Performance and Capacity Ramp-Up

Operating indicators remained favourable despite the addition of new capacity. ARPOB increased 6 per cent year on year to about Rs 67,300 per day, aided by an improved case mix and a reduction in average length of stay to 2.60 days from 2.66 days in Q1FY26.

Average occupancy rose around 100 basis points year on year but declined around 410 basis points sequentially to 41.2 per cent because of the new beds. Mature hospitals recorded 45.0 per cent occupancy and Rs 70,662 ARPOB, while new hospitals recorded 34.4 per cent occupancy and Rs 59,133 ARPOB.

Inpatient volumes grew 28 per cent year on year, outpatient volumes increased 25 per cent and deliveries rose 23 per cent.

Growth Outlook and Expansion Plans

Management reiterated guidance for more than 20 per cent Q2FY27 revenue growth and around 20 per cent medium-term revenue CAGR. It also maintained FY27 exit pre-IndAS EBITDA margin guidance of 24-25 per cent, despite margin pressure from the approximately 40 per cent capacity addition over the past two years.

Management plans to double capacity to around 5,000 beds over five years through approximately 2,500 additional beds and around Rs 22,000 million of capex, funded by internal accruals. Around 1,200 beds are under execution, with 30 per cent of incremental capacity in existing southern markets and 70 per cent in new markets, including Delhi NCR, North India, Central India and Mumbai.

Hospital Pipeline and Acquisitions

• Indore is expected to be added in Q3FY27.
• Coimbatore and Gurugram Sector-56 are planned for H2FY28.
• Gurugram Sector-44 is planned for Q1FY29.
• Pune and a Bengaluru spoke are planned for FY29.
• Malad, Mumbai is expected to open in Q1FY28 under a doctor-partner joint venture model.
• Nellore and Guntur are expected to expand the Andhra Pradesh network.

Guwahati and Warangal acquisitions contributed around Rs 380 million of revenue and around 10 per cent of Q1 EBITDA. Guwahati was EBITDA positive near company-level margins, Warangal had turned EBITDA positive, Rajahmundry was at breakeven, and Electronic City was expected to reach breakeven within two to three months.

Earnings Estimates

PL Research raised its FY27E and FY28E EBITDA estimates by 3-4 per cent. The broker's revised forecasts are as follows:

The broker expects a 22 per cent EBITDA CAGR over FY26-FY28E as new capacity ramps up, compared with 13 per cent over FY24-FY26.

Key Execution Factors

Near-term margin pressure, lower occupancy during the ramp-up of new beds and losses at recently opened units remain relevant execution factors for the thesis. The company will need to improve utilisation and profitability as its recently expanded capacity and new-market hospitals mature.